


Resolute Onyx™ DES

SHOWN TO BE SAFE AND EFFECTIVE IN HBR PATIENTS WITH ATRIAL FIBRILLATION ON 1-MONTH DAPT*1

Bleeding risk in patients on triple therapy (DAPT and oral anticoagulants [OACs]) is magnified. This subanalysis from the Onyx ONE Clear analysis assessed outcomes in atrial fibrillation (AF) patients — 87% of which were on OACs — versus patients without AF.



DESIGNED DIFFERENTLY TO PROMOTE FAST HEALING²


Single-wire design

Increases conformability and apposition³



BioLinx™ polymer

Offers superior thromboresistance⁴



Combined, these elements promote fast healing evidenced by nearly **90% strut coverage** at 30 days.⁵

Resolute Onyx is the first DES
CE indicated for 1-month DAPT
in high bleeding risk (HBR) patients

Medtronic

OPTIMISED FOR YOUR COMPLEX CLINICAL PRACTICE AND CE MARKED FOR:

1-month DAPT in HBR patients

Diabetes mellitus

In-stent restenosis (ISR)

Multivessel disease

Chronic total occlusions (CTO)

Acute coronary syndrome (ACS)

Total occlusions (TO)

Acute myocardial infarction (AMI)

Left main (LM)

Unstable angina (UA)

Small vessel (SV)

Bifurcation lesions

CE
2797

*Based on Post-hoc analysis. Results not adjusted for multiple comparisons.

[†]P-values adjusted by propensity scores for baseline differences; all other P-values are not significant.

¹ Pasupati S, et al. Ischemic and Bleeding Outcomes in Patients With vs. Without Atrial Fibrillation: Analysis From the Onyx ONE Program. Presented at TCT congress 2020.

² Roleder T, Kedhi E, Berta B, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. *Adv Interv Cardiol.* 2019;15(2):143-150.

³ Shown in independent assessment. Data on file at Medtronic.

⁴ Finn, et al. Assessment of acute thrombogenicity and albumin bindings in the Resolute Onyx Zotarolimus-Eluting Coronary Stent System. Data presented at PCR 2019.

⁵ Kirtane A, et al. One Month Dual Antiplatelet Therapy in High Bleeding Risk Patients: Primary Results of Onyx ONE Clear. Presented online at ACC 2020.

Medtronic

Europe
Medtronic Intl. Trading SARL
Tel: 41.21.802.7000

Asia Pacific
Medtronic Intl. Ltd.
Tel: 65.6436.5000

Latin America
Medtronic
Tel: 786.709.4200

[medtronic.com/OnyxONE](https://www.medtronic.com/OnyxONE)

UC202109073 ML ©2020 Medtronic. All rights reserved. Medtronic and the Medtronic logo are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. For distribution only in markets where the Resolute Onyx coronary stent has been approved. Not for distribution in Japan, France, Canada, or Australia. 10/2020

